They are not severely underfunded, you have legitimately no idea what you are talking about. The money you are talking about comes as companies get close to and enter human trials. This is a preclinical biotech company that is mostly working with cell cultures and in small labs.The problem is that for a biotech company, $ 22.5M raised (Stemsons number) means you are severely underfunded.
I’ve sad it before, It took BILLIONS before, for instance, Moderna was able to bring something to the market.
Let’s face it, by the energy and “optimism” Geoff is showing during his last presentations, Stemson is probably taking a beating in the pigs research and their hairs probably currently look like pubes at best. The size of the problem they are trying to solve is gigantic and they needed a team at least 5-10 bigger to make it for a fair game.
Goddamn the collective brain power here is insanely low. They raised a series A and were given the amount of money they needed to complete this part of their program, and as they proceed to human trials they will raise a subsequent series B to get the funding they need for humans. That's how venture capital works.
Last edited: